In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars: The Time Has Come

Executive Summary

Biosimilars' time has come--in Europe, at least. The European regulators asserted during a workshop in Paris at the beginning of December that biosimilars guidelines will be finalized before mid-2006. This will open up a market which could be worth $8 billion within five years in the EU, according to the European Generic Association (EGA).
Advertisement

Related Content

Why EPO Matters
Why EPO Matters
Bigger Deal Values by Splitting Indications: PDL's Experience
Bigger Deal Values by Splitting Indications: PDL's Experience
How Biopharma Can Flourish in a Deteriorating Environment
Amgen/Abgenix: All About a Drug
Reviewing 2005: The Top Biopharma Stories
Biogenerics Are Happening: Slowly, Product-By-Product
Biosimilars: EMEA Wants Approvals
Biosimilars: EMEA Wants Approvals

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel